BLOOD BASED BIOMARKER MARKET ANALYSIS

Blood Based Biomarker Market, By Type (Screening Biomarker, Diagnosis Biomarker, and Others), By Disease (Cancer, Neurological Disorders, and Others), By Application (Diagnostics, Drug Discovery, and Personalized Medicine), and By Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Feb 2022
Code : CMI4945
Pages :166
Formats :
Excel and PDF
Industry : Biotechnology

Blood Based Biomarker MarketSize and Trends

The global blood based biomarkers market is estimated to be valued at US$ 18.8 billion in 2022 and is expected to exhibit a CAGR of 12.8% during the forecast period (2022-2030).

Increased prevalence of cancer and neurological disorders are expected to drive the market growth during the forecast period.

The increasing the prevalence of cancer and neurological disorders are expected to drive the global blood based biomarkers market growth over the forecast period. For instance, according to the data published by World Health Organization in February 2022, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum, and prostate cancers.

Figure 2.Global Blood Based Biomarkers Market Share (%), By Application, 2022